Pharmaceutical Standards in Israel and EU Equivalents

Recommendation
13-16 May 2025
Copenhagen, Denmark
with 7 Workshops
The European Parliament accepted the so called ACAA agreement between the European Union and Israel on October 23, 2012. This agreement which had been prepared some time ago has been now finalized.
Acccording to a press release: "The ACAA agreement (Agreements on Conformity Assessment and Acceptance of industrial products) with Israel is a framework agreement that recognizes Israel industrial standards as equivalents to European standards. An appendix regarding pharmaceutical products was added to the vote. The meaning of this is that the European Union will recognize the Israeli pharmaceutical standard, and Israeli pharmaceutical products can now be marketed without delay or further inspection (in parallel to similar marketing of European drugs in Israel). Additional appendixes covering other industrial spheres will be added to the framework agreement in the near future."
Source: Press Release EurActiv
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years